In a video interview, Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, talked about suprachoroidal delivery of Regenxbio’s gene therapy RGX-314 for neovascular age-related macular degeneration.
The results presented at the ASRS annual meeting revealed that the treatment could get enough viral particles into the suprachoroidal space, which would “infect enough cells to create the biofactory that then produces something similar to ranibizumab,” Holekamp told Healio.
“We all know that the suprachoroidal injector is elegant, but it’s